S&P 500   3,335.38 (-0.48%)
DOW   27,451.81 (-0.48%)
QQQ   275.92 (-0.46%)
AAPL   114.13 (-0.72%)
MSFT   207.58 (-0.89%)
FB   262.66 (+2.27%)
GOOGL   1,465.53 (+0.47%)
AMZN   3,146.86 (-0.86%)
TSLA   418.71 (-0.59%)
NVDA   530.23 (+1.69%)
BABA   276.95 (+0.34%)
CGC   14.52 (+2.18%)
GE   6.14 (-0.97%)
MU   50.88 (+2.33%)
AMD   81.96 (+3.12%)
T   28.35 (-0.11%)
F   6.61 (-1.20%)
ACB   4.68 (-2.09%)
GILD   62.07 (-1.24%)
NFLX   494.06 (+0.69%)
DIS   125.23 (-0.60%)
BA   164.19 (-1.14%)
BAC   23.83 (-1.08%)
S&P 500   3,335.38 (-0.48%)
DOW   27,451.81 (-0.48%)
QQQ   275.92 (-0.46%)
AAPL   114.13 (-0.72%)
MSFT   207.58 (-0.89%)
FB   262.66 (+2.27%)
GOOGL   1,465.53 (+0.47%)
AMZN   3,146.86 (-0.86%)
TSLA   418.71 (-0.59%)
NVDA   530.23 (+1.69%)
BABA   276.95 (+0.34%)
CGC   14.52 (+2.18%)
GE   6.14 (-0.97%)
MU   50.88 (+2.33%)
AMD   81.96 (+3.12%)
T   28.35 (-0.11%)
F   6.61 (-1.20%)
ACB   4.68 (-2.09%)
GILD   62.07 (-1.24%)
NFLX   494.06 (+0.69%)
DIS   125.23 (-0.60%)
BA   164.19 (-1.14%)
BAC   23.83 (-1.08%)
S&P 500   3,335.38 (-0.48%)
DOW   27,451.81 (-0.48%)
QQQ   275.92 (-0.46%)
AAPL   114.13 (-0.72%)
MSFT   207.58 (-0.89%)
FB   262.66 (+2.27%)
GOOGL   1,465.53 (+0.47%)
AMZN   3,146.86 (-0.86%)
TSLA   418.71 (-0.59%)
NVDA   530.23 (+1.69%)
BABA   276.95 (+0.34%)
CGC   14.52 (+2.18%)
GE   6.14 (-0.97%)
MU   50.88 (+2.33%)
AMD   81.96 (+3.12%)
T   28.35 (-0.11%)
F   6.61 (-1.20%)
ACB   4.68 (-2.09%)
GILD   62.07 (-1.24%)
NFLX   494.06 (+0.69%)
DIS   125.23 (-0.60%)
BA   164.19 (-1.14%)
BAC   23.83 (-1.08%)
S&P 500   3,335.38 (-0.48%)
DOW   27,451.81 (-0.48%)
QQQ   275.92 (-0.46%)
AAPL   114.13 (-0.72%)
MSFT   207.58 (-0.89%)
FB   262.66 (+2.27%)
GOOGL   1,465.53 (+0.47%)
AMZN   3,146.86 (-0.86%)
TSLA   418.71 (-0.59%)
NVDA   530.23 (+1.69%)
BABA   276.95 (+0.34%)
CGC   14.52 (+2.18%)
GE   6.14 (-0.97%)
MU   50.88 (+2.33%)
AMD   81.96 (+3.12%)
T   28.35 (-0.11%)
F   6.61 (-1.20%)
ACB   4.68 (-2.09%)
GILD   62.07 (-1.24%)
NFLX   494.06 (+0.69%)
DIS   125.23 (-0.60%)
BA   164.19 (-1.14%)
BAC   23.83 (-1.08%)
Log in

Target N. V. Biotech Purchases 200,000 Shares of Radius Health Inc (NASDAQ:RDUS) Stock

Last updated on Wednesday, September 16, 2020 | 2020 MarketBeat

Radius Health Inc (NASDAQ:RDUS) major shareholder Target N. V. Biotech acquired 200,000 shares of Radius Health stock in a transaction on Monday, September 14th. The shares were bought at an average cost of $11.69 per share, for a total transaction of $2,338,000.00. Following the completion of the transaction, the insider now owns 7,355,714 shares in the company, valued at approximately $85,988,296.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Shares of RDUS stock traded up $0.28 during mid-day trading on Wednesday, reaching $12.63. 22,263 shares of the company's stock traded hands, compared to its average volume of 610,830. Radius Health Inc has a 12 month low of $10.32 and a 12 month high of $29.97. The company has a market cap of $573.70 million, a P/E ratio of -4.18 and a beta of 1.00. The company's 50-day moving average price is $12.08 and its 200-day moving average price is $13.69.

Radius Health (NASDAQ:RDUS) last announced its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.82) by ($0.13). The company had revenue of $50.11 million for the quarter, compared to the consensus estimate of $48.43 million. On average, sell-side analysts expect that Radius Health Inc will post -2.5 EPS for the current year.

RDUS has been the topic of a number of research analyst reports. Morgan Stanley reduced their price objective on shares of Radius Health from $20.00 to $19.00 and set an "equal weight" rating on the stock in a research report on Tuesday, August 25th. BidaskClub downgraded shares of Radius Health from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. HC Wainwright restated a "hold" rating and set a $28.00 target price on shares of Radius Health in a report on Tuesday, July 28th. SVB Leerink restated a "market perform" rating on shares of Radius Health in a report on Friday, August 28th. Finally, Jefferies Financial Group dropped their target price on shares of Radius Health from $17.00 to $14.00 and set a "hold" rating on the stock in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company's stock. The company currently has an average rating of "Hold" and an average price target of $21.22.

A number of institutional investors have recently made changes to their positions in the stock. Bellevue Group AG boosted its stake in Radius Health by 0.3% in the 2nd quarter. Bellevue Group AG now owns 7,007,385 shares of the biopharmaceutical company's stock worth $95,511,000 after purchasing an additional 24,000 shares in the last quarter. Vanguard Group Inc. boosted its stake in Radius Health by 2.8% in the 2nd quarter. Vanguard Group Inc. now owns 4,437,267 shares of the biopharmaceutical company's stock worth $60,480,000 after purchasing an additional 120,974 shares in the last quarter. Geode Capital Management LLC boosted its stake in Radius Health by 2.4% in the 1st quarter. Geode Capital Management LLC now owns 673,776 shares of the biopharmaceutical company's stock worth $8,758,000 after purchasing an additional 15,851 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Radius Health by 45.5% in the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 665,830 shares of the biopharmaceutical company's stock worth $9,075,000 after purchasing an additional 208,247 shares in the last quarter. Finally, Nuveen Asset Management LLC boosted its stake in Radius Health by 38.8% in the 1st quarter. Nuveen Asset Management LLC now owns 550,068 shares of the biopharmaceutical company's stock worth $7,151,000 after purchasing an additional 153,725 shares in the last quarter.

Radius Health Company Profile

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.

Read More: How to Track your Portfolio in Google Finance

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

The Next 5 Retailers on the Edge of Bankruptcy

Through no fault of theirs, the novel coronavirus has put some retailers on the edge of bankruptcy. And as you’ve seen, many have fallen over that edge including iconic names like Nieman Marcus, J.C. Penney and J.Crew.

In fact, according to the American Bankruptcy Institute, there were 560 commercial Chapter 11 filings in April. That was a 26% increase over last year. And executive director, Amy Quakenboss, suggests that there are more to come.

“As financial challenges continue to escalate amid this crisis,” observes Quakenboss, “bankruptcy is sure to offer a financial safe harbor from the economic storm.”

With no revenue walking through the door, many retailers are seeing a semblance of revenue from e-commerce sales. But for some retailers, the shutdown is more impactful because they didn’t have a strong e-commerce structure. That means that they rely more than others on brick-and-mortar sales.

The real question now is will there really be the pent-up demand that some analysts still swear is just waiting to be unleashed. It may indeed exist. Time will tell. But time is not a commodity many of these retailers have. And we’ve identified five retailers for which the clock is not in their favor.

View the "The Next 5 Retailers on the Edge of Bankruptcy".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.